2.27
-0.03
(-1.52%)
May 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 2.19 - 2.35 |
| 52 week | 1.47 - 3.45 |
| Open | 2.30 |
| Vol / Avg. | 84,094.00/2,679.00 |
| Mkt cap | 32.08M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.01* |
| Shares | 1,416.15M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Aug 23, 2013
Interim 2013 Oxford BioMedica plc Earnings Release
Feb 27, 2013
Preliminary 2012 Oxford BioMedica plc Earnings Conference Call
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -113.98% | -112.56% |
| Operating margin | -141.80% | -135.21% |
| EBITD margin | - | 58.01% |
| Return on average assets | -33.04% | -34.56% |
| Return on average equity | -46.26% | -46.67% |
| Employees | 98 | - |
| Carbon Disclosure Rating | - | - |
Address
Medawar Centre Robert Robinson Avenue The Oxford Science Park
Oxford, ENG OX4 4GA
United Kingdom - Map
+44-1865-783000 (Phone)
+44-1865-783001 (Fax)
Oxford, ENG OX4 4GA
United Kingdom - Map
+44-1865-783000 (Phone)
+44-1865-783001 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Oxford BioMedica plc is a biopharmaceutical company developing gene-based medicines and therapeutic vaccines. The Company�s LentiVector platform products include ProSavin, RetinoStat, StarGen, UshStat, EncorStat, Glaucoma-GT and MoNuDin. Its 5T4 Tumour Antigen produces TroVax and Anti-5T4 antibody. The Prime Boost�s product includes Hi-8 Mel. Its GDEPT platform produces MetXia and Anti Angiogenesis platform produces EndoAngio-GT. The Company is developing four LentiVector platform product candidates for the treatment of ocular diseases: RetinoStat for wet age-related macular degeneration (AMD); StarGen for Stargardt disease; UshStat for Usher syndrome type 1B, and EncorStat for corneal graft rejection. TroVax is a therapeutic vaccine that stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen. On February 25, 2011, the Company purchased a freehold property, United Kingdom comprising a manufacturing facility.
Officers and directors
| John Dawson | Chief Executive Officer, Executive Director | |
| Andrew J. Heath M.D., Ph.D. | Deputy Chairman and Senior Independent Director | |
| Tim Watts | Chief Financial Officer, Company Secretary, Executive Director | |
| Peter Nolan | Senior Vice President - Commercial Development, Executive Director | |
| Stuart Naylor | Chief Scientific Officer, Executive Director | |
| Alexander D. Lewis | Director - Corporate Activities and Strategy | |
| Nicholas Rodgers | Senior Independent Non-Executive Chairman of the Board | |
| Martin Diggle | Non-Executive Director | |
| Paul Blake MB, FRCP | Non-Executive Independent Director |